| abstract |
The present invention provides a compound of formula (I) wherein R 1 is —NR′R ″, wherein R ′ and R ″ are independently of each other lower alkyl, — (CH 2 ) n —C (O) NR a R b , — (CH 2 ) n -heteroaryl, — (CH 2 ) n -aryl, — (CH 2 ) n —CN, — (CH 2 ) n —O-lower alkyl or — (CH 2 ) n -cycloalkyl or R ′ and R ″ together with an N atom may contain an additional O or S heteroatom, a 5- or 6-membered non-aromatic ring (the ring is It may be unsubstituted or substituted with 1 or 2 substituents selected from the group consisting of lower alkyl, —C (O) NR a R b or — (CH 2 ) n —O-lower alkyl. may also be) to form have, and R a and R b are, independently of one another, hydrogen or lower alkyl] der ; R 2 is substituted with unsubstituted or lower alkyl or halogen, aryl or heteroaryl; n is, the compounds and pharmaceutically acceptable thereof is 0, 1, 2 or 3] The present compounds can be used in the treatment of diseases associated with the adenosine A2 receptor. |